Hospital
Bon Secours Depaul Medical Center LLC
Bon Secours Depaul Medical Center LLC was paid $11.59M by Medicaid between Jan 2018 and Mar 2021, across 267 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoBON SECOURS DEPAUL MEDICAL CENTER LLC
NORFOLK, VA 23505
NORFOLK, VA 23505
33aNPI1134137615assigned 08/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.59M
24GClaims462,730
24DCodes billed267
24AFirst – last monthJan 2018 – Mar 2021
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#46 of 80
Median peer was paid$14.69M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 141,562 | $2.52M | |
| 2019 | 194,127 | $4.48M | |
| 2020 | 103,943 | $3.76M | |
| 2021 | 23,098 | $824K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 15,894 | 13,250 | $1.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 10,262 | 8,425 | $1.28M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.7% | 8,635 | 6,835 | $1.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.7% | 5,841 | 4,382 | $1.00M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.4% | 21,667 | 5,028 | $860K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.1% | 7,331 | 6,218 | $824K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.3% | 2,388 | 2,064 | $498K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.7% | 2,683 | 2,242 | $312K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.4% | 1,200 | 1,021 | $279K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 2,625 | 2,118 | $208K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 1,047 | 860 | $189K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 1,588 | 1,350 | $185K |
255 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.3% | 3,527 | $152K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 511 | $148K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 265 | $133K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 1,151 | $130K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.1% | 3,261 | $125K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 929 | $124K |
| 59025 | Fetal non-stress test | <1% | 788 | $108K |
| 80053 | Comprehensive metabolic panel | <1% | 19,197 | $97K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,299 | $93K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 670 | $89K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 936 | $84K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,785 | $76K |
| 76642 | <1% | 739 | $72K | |
| 76830 | Ultrasound, transvaginal | <1% | 772 | $63K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,376 | $60K |
| 97162 | <1% | 2,376 | $60K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,964 | $58K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 185 | $55K |
| 93017 | <1% | 421 | $54K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,888 | $51K |
| 97014 | <1% | 1,561 | $49K | |
| 93971 | <1% | 496 | $45K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,687 | $44K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 217 | $41K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,501 | $41K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,419 | $41K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 148 | $39K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,910 | $39K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,382 | $38K |
| 93975 | <1% | 723 | $38K | |
| 97113 | <1% | 762 | $35K | |
| 71250 | <1% | 567 | $30K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,504 | $29K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,501 | $29K |
| 80061 | Lipid panel | <1% | 5,528 | $27K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,303 | $26K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,053 | $25K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,742 | $21K |
| 80050 | General health panel | <1% | 1,727 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,063 | $19K |
| 83880 | <1% | 2,291 | $19K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,689 | $17K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,942 | $16K |
| 97161 | <1% | 626 | $15K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 994 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,739 | $15K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,200 | $14K |
| 84484 | <1% | 8,576 | $13K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 357 | $13K |
| 87040 | <1% | 1,603 | $13K | |
| 84439 | <1% | 1,724 | $12K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 224 | $11K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 553 | $10K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 59 | $10K |
| 82553 | <1% | 3,673 | $10K | |
| 73564 | <1% | 1,121 | $9K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 908 | $9K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 43 | $9K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,895 | $9K |
| 85027 | <1% | 2,665 | $8K | |
| 97803 | <1% | 522 | $7K | |
| 82607 | <1% | 895 | $7K | |
| 97602 | <1% | 91 | $7K | |
| 73030 | <1% | 826 | $7K | |
| 86780 | <1% | 655 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 443 | $7K |
| 82728 | <1% | 1,378 | $7K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 206 | $6K |
| 10060 | <1% | 31 | $6K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 143 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 381 | $6K |
| 90715 | <1% | 529 | $6K | |
| 85379 | <1% | 996 | $6K | |
| 77062 | <1% | 161 | $6K | |
| 84702 | <1% | 1,532 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,926 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,912 | $5K |
| 82962 | <1% | 5,244 | $5K | |
| 72100 | <1% | 246 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,434 | $5K |
| 77061 | <1% | 123 | $5K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 27 | $4K |
| 81001 | <1% | 9,318 | $4K | |
| 82570 | <1% | 1,185 | $4K | |
| 77080 | <1% | 100 | $4K | |
| 86803 | <1% | 756 | $4K | |
| 83605 | <1% | 1,582 | $4K | |
| 73630 | <1% | 889 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,668 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,989 | $4K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $4K |
| 72110 | <1% | 141 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,799 | $4K |
| 77066 | Tomosynthesis, mammo | <1% | 325 | $4K |
| 73610 | <1% | 631 | $4K | |
| 12001 | <1% | 12 | $4K | |
| 83540 | <1% | 1,594 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 435 | $3K |
| 81025 | <1% | 7,189 | $3K | |
| 73502 | <1% | 449 | $3K | |
| J3490 | Unclassified drugs | <1% | 4,649 | $3K |
| 80076 | <1% | 1,345 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 256 | $3K |
| 77065 | Tomosynthesis, mammo | <1% | 299 | $3K |
| 83550 | <1% | 1,272 | $3K | |
| 82746 | <1% | 573 | $3K | |
| 82565 | <1% | 884 | $3K | |
| 97802 | <1% | 185 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,712 | $3K |
| 73130 | <1% | 545 | $3K | |
| 99218 | <1% | 577 | $2K | |
| 80047 | <1% | 567 | $2K | |
| 86850 | <1% | 1,248 | $2K | |
| 84153 | <1% | 434 | $2K | |
| 85610 | <1% | 2,408 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 228 | $2K |
| 82043 | <1% | 1,028 | $2K | |
| 97116 | <1% | 338 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,459 | $2K |
| 87340 | <1% | 670 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,457 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 13 | $2K |
| 81003 | <1% | 5,206 | $2K | |
| 86900 | <1% | 1,516 | $2K | |
| 87077 | <1% | 1,758 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 254 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,256 | $1K |
| 29515 | <1% | 12 | $1K | |
| 76870 | <1% | 16 | $1K | |
| 70486 | <1% | 31 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,803 | $1K |
| 83021 | <1% | 294 | $1K | |
| 83735 | <1% | 3,183 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,109 | $1K |
| 87081 | <1% | 1,193 | $1K | |
| 86901 | <1% | 1,515 | $980.63 | |
| 84703 | <1% | 1,852 | $964.77 | |
| 93970 | <1% | 21 | $916.66 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,068 | $914.26 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,255 | $909.88 |
| 82550 | <1% | 3,961 | $905.52 | |
| 83690 | <1% | 5,385 | $863.09 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 687 | $852.64 |
| 85652 | <1% | 432 | $826.04 | |
| 93225 | <1% | 28 | $795.31 | |
| 97016 | <1% | 33 | $769.89 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 63 | $755.10 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 516 | $725.19 |
| 86140 | <1% | 127 | $704.63 | |
| 87186 | <1% | 1,393 | $658.11 | |
| 87481 | <1% | 167 | $657.49 | |
| 85730 | <1% | 1,163 | $648.51 | |
| 84550 | <1% | 369 | $597.78 | |
| 88142 | <1% | 26 | $589.08 | |
| 88307 | <1% | 52 | $582.98 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 858 | $565.91 |
| 86762 | <1% | 288 | $531.09 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 997 | $500.93 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,301 | $486.85 |
| 97165 | <1% | 13 | $470.56 | |
| 85014 | <1% | 549 | $464.44 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 936 | $457.21 |
| 87070 | <1% | 519 | $448.62 | |
| 82105 | <1% | 45 | $443.89 | |
| 73560 | <1% | 28 | $433.09 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,044 | $414.88 |
| 73110 | <1% | 167 | $399.99 | |
| 93226 | <1% | 28 | $397.62 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,851 | $388.59 |
| 96376 | <1% | 2,106 | $363.59 | |
| 87210 | <1% | 2,217 | $361.07 | |
| 84425 | <1% | 71 | $349.70 | |
| 74018 | <1% | 25 | $347.37 | |
| 80143 | <1% | 41 | $329.66 | |
| 85660 | <1% | 306 | $328.12 | |
| 86300 | <1% | 26 | $318.28 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,584 | $300.52 |
| 82652 | <1% | 22 | $274.93 | |
| 82274 | <1% | 59 | $262.35 | |
| 90686 | <1% | 139 | $249.08 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16 | $247.54 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,269 | $247.39 |
| 83001 | <1% | 14 | $216.42 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 108 | $213.30 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 970 | $204.03 |
| 99152 | <1% | 106 | $191.50 | |
| 94762 | <1% | 537 | $178.05 | |
| 73140 | <1% | 39 | $168.75 | |
| 84165 | <1% | 29 | $159.76 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,747 | $159.68 |
| 80179 | <1% | 39 | $156.63 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,692 | $152.36 |
| 86592 | <1% | 143 | $149.47 | |
| 82950 | <1% | 52 | $149.42 | |
| 84132 | <1% | 339 | $136.59 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,410 | $134.92 |
| 84403 | <1% | 15 | $130.88 | |
| 84481 | <1% | 36 | $124.99 | |
| 83970 | <1% | 14 | $112.82 | |
| 90653 | <1% | 75 | $110.05 | |
| 84100 | <1% | 227 | $96.63 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 623 | $96.54 |
| 82077 | <1% | 222 | $90.37 | |
| 73080 | <1% | 26 | $88.65 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 22 | $81.09 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 94 | $79.72 |
| 99153 | Mod sedat endo service >5yrs | <1% | 57 | $73.20 |
| 88304 | <1% | 42 | $69.59 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 843 | $59.54 |
| 87205 | <1% | 94 | $57.89 | |
| 84520 | <1% | 315 | $57.55 | |
| 74022 | <1% | 34 | $56.25 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 683 | $51.86 |
| 82947 | <1% | 298 | $48.13 | |
| J1815 | Injection, insulin, per 5 units | <1% | 367 | $42.98 |
| 86787 | <1% | 14 | $27.47 | |
| 88342 | <1% | 80 | $26.95 | |
| 84295 | <1% | 283 | $24.10 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 209 | $23.29 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 248 | $22.74 |
| 82435 | <1% | 280 | $22.34 | |
| 85018 | <1% | 35 | $22.25 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 188 | $21.85 |
| 85045 | <1% | 17 | $18.16 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 506 | $16.04 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 96 | $13.05 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 133 | $12.82 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 50 | $5.55 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 35 | $4.81 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 49 | $3.96 |
| 82272 | <1% | 15 | $3.79 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 33 | $3.16 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 46 | $3.13 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 73 | $2.01 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 19 | $0.70 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 29 | $0.22 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 555 | $0.00 |
| 96367 | 0% | 17 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 736 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 19 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 60 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 18 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 14 | $0.00 |
| 72050 | 0% | 13 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 267 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 188 | $0.00 |
| A9270 | Non-covered item or service | 0% | 3,573 | $0.00 |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | 0% | 18 | $0.00 |
| 94761 | 0% | 26 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 115 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 163 | $0.00 |
| C1769 | Guide wire | 0% | 43 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 12 | $0.00 |
| 87147 | 0% | 61 | $0.00 | |
| 82803 | 0% | 33 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.